指南与共识消化、代谢与肾脏急症

AACC关于在临床实验室实施和解读SARS-CoV-2紧急使用授权与实验室自建检测血清学检测的实用建议

AACC Practical Recommendations for Implementing and Interpreting SARS-CoV-2 Emergency Use Authorization and Laboratory-Developed Test Serologic Testing in Clinical Laboratories.
指南 / 共识 · Clin Chem · 2021-01-01
一句话结论AACC专家小组就SARS-CoV-2血清学检测的实施与解读提出实用建议,涵盖四种检测适应证、结果解读与报告注释及正交检测的作用。

美国临床化学协会(AACC)召集来自临床化学、微生物学和免疫学实验室、体外诊断行业及监管机构的专家小组,针对SARS-CoV-2紧急使用授权(EUA)和实验室自建检测(LDT)血清学检测在临床实验室的实施与解读提出实用建议。文件讨论了现有EUA血清学检测和平台、检测设计信息、抗体类别(包括中和抗体)及SARS-CoV-2体液免疫应答,描述了EUA和LDT检测的验证与确认及质量管理方法,并列出四种血清学检测适应证。文件还就结果解读、报告注释和正交检测的作用提出建议,旨在为实验室专业人员和医疗工作者提供综合参考,并可用于未来类似场景的规划。

要点

  • AACC专家小组就SARS-CoV-2 EUA和LDT血清学检测在临床实验室的实施与解读提出实用建议。
  • 文件列出四种血清学检测适应证,并讨论结果解读、报告注释和正交检测的作用。
  • 文件描述EUA和LDT检测的验证与确认及质量管理方法。
  • 文件讨论现有EUA血清学检测和平台、检测设计、抗体类别(包括中和抗体)及体液免疫应答。
  • 文件旨在为实验室专业人员和医疗工作者提供综合参考,并可用于未来类似场景的规划。

适用人群与场景

  • 临床实验室专业人员和医疗工作者,涉及临床化学、微生物学和免疫学实验室、体外诊断行业及监管机构。

研究设计与关键结果

  • AACC召集来自临床化学、微生物学和免疫学实验室、体外诊断行业及监管机构的专家小组,就SARS-CoV-2 EUA和LDT血清学检测的实施与解读提供实用建议。
  • 文件讨论现有EUA血清学检测和平台、检测设计信息、抗体类别(包括中和抗体)及SARS-CoV-2体液免疫应答。
  • 文件描述EUA和LDT检测的验证与确认及质量管理方法,并列出四种血清学检测适应证。
  • 文件就结果解读、报告注释和正交检测的作用提出建议。

证据类型、等级与局限

  • 证据类型:指南(AACC专家小组实用建议)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 文件旨在为实验室专业人员和医疗工作者提供综合参考,以在临床实验室中适当实施SARS-CoV-2血清学检测并解读检测结果。
  • 文件指出,鉴于病媒传播或呼吸道病原体相关暴发更频繁发生,该文件可作为未来类似场景规划的有用资源。

指南或共识出处

  • AACC Practical Recommendations for Implementing and Interpreting SARS-CoV-2 Emergency Use Authorization and Laboratory-Developed Test Serologic Testing in Clinical Laboratories(AACC,年份原文未写明)

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: The clinical laboratory continues to play a critical role in managing the coronavirus pandemic. Numerous US Food and Drug Administration emergency use authorization (EUA) and laboratory-developed test (LDT) serologic assays have become available. The performance characteristics of these assays and their clinical utility continue to be defined in real time during this pandemic. The AACC convened a panel of experts from clinical chemistry, microbiology, and immunology laboratories; the in vitro diagnostics industry; and regulatory agencies to provide practical recommendations for implementation and interpretation of these serologic tests in clinical laboratories.

CONTENT: The currently available EUA serologic tests and platforms, information on assay design, antibody classes including neutralizing antibodies, and the humoral immune responses to SARS-CoV-2 are discussed. Verification and validation of EUA and LDT assays are described, along with a quality management approach. Four indications for serologic testing are outlined. Recommendations for result interpretation, reporting comments, and the role of orthogonal testing are also presented.

SUMMARY: This document aims to provide a comprehensive reference for laboratory professionals and healthcare workers to appropriately implement SARS-CoV-2 serologic assays in the clinical laboratory and to interpret test results during this pandemic. Given the more frequent occurrence of outbreaks associated with either vector-borne or respiratory pathogens, this document will be a useful resource in planning for similar scenarios in the future.

来源:Clin Chem,查看原文。版权归原作者所有。

参考来源

  1. Zhang YV, Wiencek J, Meng QH, et al. AACC Practical Recommendations for Implementing and Interpreting SARS-CoV-2 Emergency Use Authorization and Laboratory-Developed Test Serologic Testing in Clinical Laboratories. Clin Chem. 2021. PMID: 34470034. doi:10.1093/clinchem/hvab051

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。